Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cogent Biosciences, Inc. Director's Dealing 2019

Jul 17, 2019

31688_dirs_2019-07-17_9de42c17-82cf-409d-8649-aeb3fe0cd0d5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Unum Therapeutics Inc. (UMRX)
CIK: 0001622229
Period of Report: 2019-07-15

Reporting Person: Sachs Jessica (Chief Medical Officer)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $4.39 2027-05-18 Common Stock (63688) Direct
Stock Option (Right to Buy) $9.77 2027-10-27 Common Stock (12737) Direct
Stock Option (Right to Buy) $12.00 2028-03-28 Common Stock (21017) Direct
Stock Option (Right to Buy) $3.60 2029-04-19 Common Stock (21017) Direct
Stock Option (Right to Buy) $3.52 2029-04-24 Common Stock (22419) Direct

Footnotes

F1: 25% of the shares vested on April 18, 2018, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer.

F2: 25% of the shares vested on October 27, 2018, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer.

F3: 25% of the shares vested March 16, 2019, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer.

F4: 25% of the shares shall vest on April 19, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer.

F5: 25% of the shares shall vest on April 24, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer.